- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03616548
Surveillance of Allograft Rejection After Intestinal Transplantation Using Endoscopy
Surveillance of Allograft Rejection After Intestinal Transplantation Using a Magnifying Endoscopy With Narrow Band Imaging Scoring System ("VENCH" Score)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study design
This cohort study was conducted prospectively and approved by the ethics committee of Far Eastern Memorial Hospital (IRB No. FEMH-105023-F). Consecutive patients who received IT between November 2016 and September 2017 were enrolled. The inclusion criteria were as followings: post-IT patients older than 7-year-old, and with informed consent for endoscopy and biopsy. Those with bleeding tendency (platelet count <80k/ul, or prothrombin time international normalized ratio >1.5), without informed consent, or leukopenia (absolute neutrophil count <1,500/ul) were excluded.
Endoscopic and histological grading for allograft rejection Endoscopic surveillance was carried out after IT twice a week during the first month, once a week in the second month and then once per month until ileostomy closed. IEE examinations were performed with magnifying endoscopy (ME) which has powerful 80 times optical magnification under narrow-band imaging (NBI) system (Evis Lucera CLV-260NBI, GIF-H260Z endoscopy, Olympus Medical Systems Corp, Tokyo, Japan).14 ME was intubated through chimney ileostomy to anastomosis site to evaluate the changes of superficial mucosal surface and vascular architecture. Biopsy samples were taken from endoscopically suspicious rejection areas for histological examination. All the endoscopic procedures were done by one experienced endoscopist (C.S-C.) who was blinded to the histological reports.
All the histological reports were carried out by one experienced pathologist (C.C.-T.). The severity of histological rejection was graded according to followings:11 1) Indeterminate:
minimal histological changes including localized inflammatory infiltrate, crypt epithelial injury, increased crypt epithelial apoptosis but less than 6 apoptotic bodies/10crypts, no to minimal architectural distortion, no mucosal ulceration, or changes insufficient for the diagnosis of mild rejection; 2) Mild: mild localized inflammatory infiltrate with activated lymphocytes, mild crypt epithelial injury, increased crypt epithelial apoptosis > 6 apoptotic bodies/10crypts, mild architectural distortion but no mucosal ulceration; 3) Moderate: widely dispersed inflammatory infiltrate in lamina propria, diffuse crypt epithelial injury, increased crypt apoptosis with focal confluent apoptosis, more prominent architectural distortion, possible mild to moderate intimal arteritis, no mucosal ulceration; 4) Severe: features of moderate ACR, possible ulceration and denudation of mucosa, severe intimal arteritis or transmural arteritis may be seen. We classified those with apoptotic body≦1/10crypts and without other findings associated with indeterminate, mild, moderate to severe rejection as no rejection.
We used a novel endoscopic scoring system to record the architectural changes of microsurface and microvascularity of mucosa (Table 1). The observed endoscopic findings were recorded by the following five components ("V-E-N-C-H") graded 0 to 2 (Figure 1): 1) "V" (villi appearance): string-like (V-0), tongue-like (V-1), dome-like (V-2); 2) "E" (erythema of mucosa): no redness (E-0), sporadic (E-1), diffuse (E-2); 3) "N" (network of capillary): normal capillary loops (N-0), meandering caliber of capillary loops and loss of capillary loops in <50% villi under one maximal ME view (N-1), loss of capillary loops >50% villi under one maximal
ME view (N-2); 4) "C" (crypt widening): narrow (C-0), slightly widened within a width of one villi (C-1), markedly widened beyond a width of one villi (C-2); 5) "H" (heterogeneity of mucosal change): minimal (H-0), patch (H-1), diffuse (H-2).
Statistical analysis The continuous variables were expressed as mean ± standard deviation, whereas categorical variables were summarized as count (%). Pearson's correlation coefficient was used to analyze the severity of rejection between endoscopic scoring system and histological grading system. The significance levels were defined as p value <0.05 and the statistical analysis was performed using STATA software (version 11.0; Stata Corp, College Station, TX, USA).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
New Taipei City, Taiwan
- Recruiting
- Far Eastern Memorial Hospital
-
Contact:
- Chen-Shuan Chung, MD, M.Sc
- Email: chugnchenshuan_3@yahoo.com.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Post-small intestinal transplantation patients
- Older than 7-year-old
- With informed consent for endoscopy and biopsy
Exclusion Criteria:
- Bleeding tendency (platelet count <80k/ul, PTINR >1.5)
- Without informed consent for endoscopy and biopsy
- Leukopenia (ANC <1,500/ul)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Intestinal transplantation
Magnifying endoscopy under NBI system via chimney ileostomy after intestinal transplantation using a novel VENCH scoring system
|
Magnifying endoscopy under narrow band imaging system via chimney ileostomy after intestinal transplantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation of endoscopic scoring system with severity of histological rejection
Time Frame: 1 year
|
Endoscopists who are blinded to the clinical data recorded the imaging findings based on the V-E-N-C-H score, and the pathologists who are blinded to the clinical data reported the endoscopic biopsy specimen findings about rejection.
Pearson's correlation test is used to evaluate the correlation between endoscopic and pathological findings.
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Chen Shuan Chung, MD, MSc, Department of Internal Medicine, Far Eastern Memorial Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- FEMH-105023-F
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rejection of an Intestine Transplant
-
Medical University of ViennaMedical University InnsbruckCompletedAntibody-mediated Rejection | Late Rejection of Renal TransplantAustria
-
University of ManitobaCanadian Institutes of Health Research (CIHR); Canadian National Transplant...CompletedKidney Transplant; Complications | Rejection of Renal TransplantAustralia, Canada
-
Wake Forest University Health SciencesStanford UniversityCompletedRenal Transplant | Rejection Acute Renal | Rejection Chronic Renal | Rejection of Renal Transplant | Renin-Angiotensin SystemUnited States
-
Fundación Pública Andaluza para la Investigación...Sociedad Andaluza de Trasplantes de Organos y TejidosCompletedRenal Transplant Rejection | Other Complication of Kidney TransplantSpain
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI); University of UtahRecruitingAntibody Mediated Rejection of Lung TransplantUnited States
-
Eledon PharmaceuticalsRecruitingPrevention of Rejection in Kidney TransplantUnited States, Australia, Canada, United Kingdom, Brazil
-
Ha Young OhBaxter Healthcare CorporationUnknownAcute Rejection of Renal Transplant | Delayed Function of Renal Transplant | Primary Nonfunction of Renal TransplantKorea, Republic of
-
Stanford UniversityKaiser Foundation Research InstituteCompletedLung Transplant Rejection | Cardiac Transplant RejectionUnited States
-
Rush University Medical CenterCareDxCompletedKidney Transplant Rejection | Pancreas Transplant RejectionUnited States
-
Medical College of WisconsinNational Heart, Lung, and Blood Institute (NHLBI); University of California... and other collaboratorsCompletedCardiovascular Disease | Heart Transplant Failure and Rejection | Cardiac Transplant Rejection | Acute Rejection of Cardiac TransplantUnited States
Clinical Trials on Endoscopic surveillance
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Nederlandse Barrett REgistratie StichtingRecruitingBarrett Esophagus | Barrett Esophagus AdenocarcinomaNetherlands
-
Vall Hebron Insitut RecercaNot yet recruitingBladder CancerSpain
-
Assistance Publique - Hôpitaux de ParisUnité de Recherche Clinique Necker Cochin, FranceCompletedBarrett Oesophagus | Low Grade DysplasiaFrance
-
Fundacin Biomedica Galicia SurRecruiting
-
University of AlbertaCompleted
-
University of SydneyMelanoma and Skin Cancer Trials LimitedCompleted
-
Intermountain Health Care, Inc.UnknownDeep Vein Thrombosis | Venous Thromboembolism | Trauma, MultipleUnited States
-
The University of Texas Health Science Center at...CompletedBladder CancerUnited States
-
University Health Network, TorontoActive, not recruiting
-
VA Office of Research and DevelopmentNot yet recruitingHigh-Grade Early-Stage Bladder CancerUnited States